JPS60156608A - Ointment - Google Patents
OintmentInfo
- Publication number
- JPS60156608A JPS60156608A JP59012696A JP1269684A JPS60156608A JP S60156608 A JPS60156608 A JP S60156608A JP 59012696 A JP59012696 A JP 59012696A JP 1269684 A JP1269684 A JP 1269684A JP S60156608 A JPS60156608 A JP S60156608A
- Authority
- JP
- Japan
- Prior art keywords
- ointment
- water
- gentamicin sulfate
- alcohol
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 26
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 6
- 150000002430 hydrocarbons Chemical class 0.000 claims abstract description 6
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract description 4
- 239000003246 corticosteroid Substances 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 1
- 239000003470 adrenal cortex hormone Substances 0.000 abstract description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract description 8
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- JXAZAUKOWVKTLO-UHFFFAOYSA-L sodium pyrosulfate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)OS([O-])(=O)=O JXAZAUKOWVKTLO-UHFFFAOYSA-L 0.000 abstract 2
- 229960004311 betamethasone valerate Drugs 0.000 abstract 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 abstract 1
- 229960000631 hydrocortisone valerate Drugs 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 17
- 239000002244 precipitate Substances 0.000 description 10
- 239000013078 crystal Substances 0.000 description 8
- -1 furopylene gelicol Chemical compound 0.000 description 6
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 6
- 235000010262 sodium metabisulphite Nutrition 0.000 description 6
- 229940070710 valerate Drugs 0.000 description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 6
- 239000008213 purified water Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000001780 adrenocortical effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 102000008071 Mismatch Repair Endonuclease PMS2 Human genes 0.000 description 1
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は軟膏に関し、更に詳しくは硫酸ゲンタマイシン
と副腎皮質ホルモンを含有する軟膏に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to ointments, and more particularly to ointments containing gentamicin sulfate and corticosteroids.
炎症性皮崩疾患の治療に使用する軟膏には、。Ointments used to treat inflammatory skin disintegration diseases include:
患部に対して消炎、止痛作用を有する副腎皮質ホルモン
と患部の細菌感染を防止する抗生物質とを併用するのが
好ましく、また両者は基剤中に溶解状態で存在している
のが効果的である。It is preferable to use adrenocortical hormones, which have anti-inflammatory and analgesic effects on the affected area, and antibiotics, which prevent bacterial infection in the affected area, in combination, and it is effective for both to be present in a dissolved state in the base. be.
しかしながら、抗生物質として硫酸ゲンタマイシンを選
定し、これと副腎皮質ホル、モンを併用する場合、硫酸
ゲンタマイシンは水には極めてよく溶解するがアルコー
ル類には溶解しないし、副腎皮質ホルモンはアルコール
類、に溶解するが水には溶解せず、アルコール類、と水
の混合比を変化させるだけでは硫酸ゲンタマイシンと副
腎皮質ホルモンとの双方を溶解することはできない。However, when selecting gentamicin sulfate as an antibiotic and using it together with adrenal corticosteroids, gentamicin sulfate is extremely soluble in water but not in alcohol; It is soluble, but not in water, and it is not possible to dissolve both gentamicin sulfate and adrenal corticosteroid simply by changing the mixing ratio of alcohol and water.
また、硫酸ゲンタマイシンと副腎皮質ホルモンの双方を
溶解している軟膏を調製するには多量の界面活性剤を必
要とするが、多、量の界面活性剤の使用は副腎皮質ホル
モンの作用を低下させてしまう。In addition, a large amount of surfactant is required to prepare an ointment that dissolves both gentamicin sulfate and corticosteroid, but the use of a large amount of surfactant may reduce the effect of corticosteroid. It ends up.
従って、従来は硫酸ゲンタマイシンと副腎皮質ホルモン
のいずれを為または双方を結晶のまま基剤中に分散して
軟膏を調製することが多かった。Therefore, in the past, ointments were often prepared by dispersing either or both of gentamicin sulfate and adrenocortical hormone in a base in the form of crystals.
本発明者らは、これら従来品の欠点を解消すべぐ鋭意研
究した結果、アルコール類と水の割合をある範囲に限定
ｔ、少量のピ・硫酸ナトリウムを配合することによシ硫
ぼゲンタマイシンと副腎皮質ホルモンの双方を溶解状態
で含有し、炎症性皮膚疾患などの治療に有効な軟膏を調
製することに成功し、本発明を完成した。As a result of intensive research to eliminate these drawbacks of conventional products, the inventors of the present invention found that by limiting the ratio of alcohol and water to a certain range and adding a small amount of sodium sulfate, gentamicin The present invention has been completed by successfully preparing an ointment that contains both adrenal cortical hormones in a dissolved state and is effective in treating inflammatory skin diseases.
本発明は、アルコール類と水を１：１〜９：１の割合で
２．０〜１０．０重量部、界面活性剤を０．１重量部か
らなる混合物を基剤とし、製品１２中にｍｆゲンタマイ
シン０．２〜５〜力価と副腎皮質ホルモン０２〜５■を
含有させることを特徴とする軟膏である。The present invention is based on a mixture of alcohol and water in a ratio of 1:1 to 9:1, consisting of 2.0 to 10.0 parts by weight and 0.1 part by weight of a surfactant. This ointment is characterized by containing mf gentamicin in a titer of 0.2 to 5 and adrenocortical hormone 02 to 5.
ここにおいて、副腎皮質ホルモンとは、ヒドロコルチゾ
ン、酪酸ヒドロコルチゾン、酪［フロピオン酸ヒドロコ
ルチゾン、吉草ばベタメタシン。Here, adrenocortical hormones include hydrocortisone, hydrocortisone butyrate, hydrocortisone butypropionate, and betamethacin.
グレードニジロン、酢酸デキサメタシン、フルオシノ″
Ａ７″′トート・ トリア”ジノ°７アセト＝ドなどの
、水にほとんど溶解しない副腎皮質ホルモンをいう。Grade Nigiron, Dexamethacin Acetate, Fluocino''
Refers to adrenal cortical hormones that are hardly soluble in water, such as A7'''totria'' dino°7 acetate.
アルコール類トは、エタノール、インプロパノ、−ル、
フロパノール、ベンジルアルコールナトの一価のアルコ
ール、フロピレンゲリコール、エチレンクリコール、グ
リセリン、ブタンジオール。Alcohols include ethanol, inpropanol,
Furopanol, benzyl alcohol, monohydric alcohol, furopylene gelicol, ethylene glycol, glycerin, butanediol.
ヘキサトリオール、プロピレン〆す、コールカーボネー
トなどの多価アルコールおよびその訪樽体をいう。Refers to polyhydric alcohols such as hexatriol, propylene alcohol, and coal carbonate, and their derivatives.
界面活性剤とは、油性軟膏の調製に利用することができ
る界面活性剤であればよいが、就中、ポリオキシエチレ
ンソルビタン脂肪酸エステル、ンルビタン脂肪酸エステ
ル、グリセリン脂肪酸エステル、プロピレングリコール
脂肪酸エステルなどで代表される非イオン性界面活性剤
〔たとえば、ニラコールＴＳＩＯ，ニラコールｓｏ ｉ
ｏ、ニラコールＭＧＥ＋ 、 ニラコールＰＭＳ （
いずれも商品名１日本ザーファクタント工業株式会社製
）〕を使用することが好ましい。The surfactant may be any surfactant that can be used in the preparation of oil-based ointments, and representative examples include polyoxyethylene sorbitan fatty acid ester, nrubitan fatty acid ester, glycerin fatty acid ester, propylene glycol fatty acid ester, etc. nonionic surfactants [e.g., niracol TSIO, niracol so i
o, Niracol MGE+, Niracol PMS (
In both cases, it is preferable to use product name 1 (manufactured by Nippon Surfactant Industries Co., Ltd.).
高級パラフィン系炭化水素とは、軽質流動パラフィン＋
ａ動パラフィン、白色ワセリン、パラフィン、セレシ
ンなどの、炭素数が１６〜４０程度のパラフィン系炭化
水素をいう二
本発明の軟膏は、前記の組成の範囲内において硫酸ゲン
タマイシンと副腎皮質ホルモンの双方を溶解状態で含有
し、薬効発現の改善が認められるが、特に好ましい組成
は、基剤がアルコール類と水を合わせて３０〜ＺＯ重量
部（そのうち水０．５〜３．０重量部）、界面活性剤０
５〜２．５重量部。High paraffin hydrocarbons include light liquid paraffin +
The ointment of the present invention is made of paraffinic hydrocarbons having about 16 to 40 carbon atoms, such as a-motor paraffin, white petrolatum, paraffin, and ceresin. When contained in a dissolved state, improvement in the expression of medicinal efficacy has been observed, but a particularly preferred composition is that the base contains 30 to 30 parts by weight of ZO (including 0.5 to 3.0 parts by weight of water) including the alcohol and water, and the interface Activator 0
5-2.5 parts by weight.
高級パラフィン系炭化水素８００〜９５．０重量部。800 to 95.0 parts by weight of higher paraffinic hydrocarbon.
ピロ亜硫酸ナトリウム００２〜０．０４重量部からなり
、硫酸ゲンタマイシン０．２〜５■力価と副腎皮質ホル
モン０．２〜５ ｙｙが製品１ｆ中に含有されているも
のである。The product 1f contains 0.2 to 0.04 parts by weight of sodium pyrosulfite, a titer of gentamicin sulfate of 0.2 to 5 yy, and a titer of 0.2 to 5 yy of adrenocortical hormone.
なお、アルコール類と水との割合は前記のとおが可能な
限シ水の配合量は多□い程よい。Note that the ratio of alcohol to water is as high as possible, and the larger the amount of water, the better.
また、ピロ亜硫叡ナトリウムは、前記の範囲内で、配合
する水の量に応じて適宜増減して配合することができる
が、０．０２重量部以下の配合では硫酸ゲンタマイシン
の溶解性を高める作用が低く、０．２重量部を超える配
合ではそれ自体の溶解が不可能となる。In addition, sodium pyrosulfite can be blended within the above range, increasing or decreasing as appropriate depending on the amount of water to be blended, but if it is blended at 0.02 parts by weight or less, it increases the solubility of gentamicin sulfate. Its effectiveness is low, and if it exceeds 0.2 parts by weight, it cannot be dissolved by itself.
本発明の軟膏は、たとえば次のようにして調製すること
ができる。The ointment of the present invention can be prepared, for example, as follows.
すなわち、副腎皮質ホルモンを加温下にアルコール類に
溶解し、これをあらかじめ加温、融解した高級パラフィ
ン系炭化水素と界面活性剤の混液に加えて加温下に攪拌
混合する。この混合物に、別途に調製した硫酸ゲンタマ
イシンとピロ亜硫酸ナトリウムの水溶液を加えて攪拌し
ながら冷却して本発明の軟膏を調製することができる。That is, adrenal cortical hormone is dissolved in alcohol under heating, and this is added to a mixture of higher paraffinic hydrocarbon and surfactant that has been heated and melted in advance, and the mixture is stirred and mixed under heating. The ointment of the present invention can be prepared by adding a separately prepared aqueous solution of gentamicin sulfate and sodium pyrosulfite to this mixture and cooling it while stirring.
硫酸ゲンタマイシンとピロ亜硫酸ナトリウムの水溶液を
副腎皮質ホルモンのアルコール類溶液に添加することも
できるが、この場合には硫酸ゲンタマイシンと副腎皮質
ホルモンが一時的に析出す水溶液を混溶することか望ま
しい。An aqueous solution of gentamicin sulfate and sodium pyrosulfite can be added to an alcoholic solution of adrenocortical hormone, but in this case, it is preferable to mix gentamicin sulfate and an aqueous solution in which adrenocortical hormone is temporarily precipitated.
本発明の軟膏は、硫酸ゲンタマイシンと副腎皮質ホルモ
ンの双方を溶解状態で含有するので、これら薬物の放出
性がよく、湿疹、皮膚炎、伝染性膿痴疹、化膿性皮疹を
伴った尋常性座癒、熱傷などの治療に極めて有効である
。Since the ointment of the present invention contains both gentamicin sulfate and adrenocortical hormone in a dissolved state, it has good release properties and is effective for treating eczema, dermatitis, impetigo contagiosum, and acne vulgaris accompanied by purulent eruption. It is extremely effective in healing and treating burns.
以下、試験例と実施例を挙げて本発明を具体的に説明す
る。The present invention will be specifically explained below with reference to Test Examples and Examples.
試験例１
第１表の処方によシ後記実施例１に準じて軟膏を調製し
て検体Ａ’、Ｂ、Ｃ！、Ｄ、Ｅとし、調製直後と室温で
１ｔ月保存後硫酸ゲンタマイシンと吉草酸ベタメタシン
の結晶の析出の有無を観察した。Test Example 1 Samples A', B, and C were prepared by preparing ointment according to the recipe in Table 1 and following Example 1 below. , D, and E, and the presence or absence of precipitation of crystals of gentamicin sulfate and betamethacin valerate was observed immediately after preparation and after storage for 1 ton at room temperature.
その結果を第２表に示す。The results are shown in Table 2.
プロピレングリコールと精製水の割合を種々変化させて
みたが、硫酸ゲンタマイシンと吉草酸ベタメタシンの双
方を同時に溶解することはできなかった。Although we tried varying the ratio of propylene glycol and purified water, we were unable to dissolve both gentamicin sulfate and betamethacin valerate at the same time.
第２表 薬物の溶解性 註） Ｘ：析出物を認めた。Table 2 Drug solubility Note) X: Precipitates were observed.
○：析出物を認めなかった。○: No precipitate was observed.
＊：＠製置後に硫酸ゲンタ１イク／の樹脂状の析出物を
視認した。*: @Resinous precipitates of Gentaic sulfate were visually observed after manufacture.
肴肴：室温１ケ月保存後の偏光顕微鏡観察によシ吉草酸
ベタメタシンの結晶の析出を認めた。Appetizer: After storage at room temperature for 1 month, observation using a polarizing microscope revealed that crystals of betamethacin valerate were precipitated.
試験例２
第３表の処方により後記実施例１に準じて軟膏を調製し
て検体Ｆ、Ｇ、Ｈ，Ｉ、Ｊとし、調製直後と室温で１ｔ
月保存後硫酸ゲンタマイシンと吉草酸ベタメタシンの結
晶の析出の有無を観察した。Test Example 2 Samples F, G, H, I, and J were prepared by preparing ointment according to Example 1 described below according to the formulation in Table 3, and 1 ton was prepared immediately after preparation and at room temperature.
After storage for months, the presence or absence of precipitation of crystals of gentamicin sulfate and betamethacin valerate was observed.
その結果を第４表に示す。The results are shown in Table 4.
註） ×、析出物を認めた。Note) x: Precipitates were observed.
○：析出物を認めなかった０
チ：調製直後に硫酸ゲンタマイシンの樹脂状の析出物を
視認した。○: No precipitate was observed 0 H: Resin-like precipitate of gentamicin sulfate was visually observed immediately after preparation.
実施例１
白色ワセリン ９２．７グ、ニラコールＴＳ１０ ０．
１ｔ、ニラコールＰＭＳ２．Ｏｆを加温融解して油相成
分Ａを調製した。Example 1 White petrolatum 92.7g, Niracol TS10 0.
1t, Niracol PMS2. Oil phase component A was prepared by heating and melting Of.
次に加温下に吉草酸ベタメタシン ｏ、ｉｒをプロピレ
ングリコール ４．Ｏｖに溶解し、これを油相成分Ａに
加えて攪拌した。これに、硫酸ゲンタマ亜
イシン０．１タカ価とピロ声酸ナトリウム０．０３１を
精製水１ｔに溶解した溶液を加えて撹拌して十分に分散
させた後、更に攪拌しながら冷却して軟膏１００ｆを得
た。Next, add betamethacin valerate o, ir to propylene glycol while heating.4. This was added to oil phase component A and stirred. To this, a solution of 0.1 taka value of gentamasinous sulfate and 0.031 sodium pyrovoate dissolved in 1 t of purified water was added and stirred to sufficiently disperse the mixture, and then cooled with further stirring to make an ointment of 100 f. I got it.
この軟膏は硫酸ゲンタマイシンまたは吉草酸ベタメタシ
ンの結晶もしくは析出物が認められなかった０
実施例２
酪酸プロピオン酸ヒドロコルチゾン ０１２硫酸ケンタ
マインン ０１７力価
プロピレングリコール ４．０２
精製水 １．０２
ニノコール８０１０ ０．５１ｉ’
流動パラフイン １０．Ｏｒ
計 １００．Ｏｒ
実施例１に準じて上記配合の軟膏を調製した。No crystals or precipitates of gentamicin sulfate or betamethacin valerate were observed in this ointment.Example 2 Hydrocortisone butyrate propionate 012 Kentamine sulfate 017 Potency propylene glycol 4.02 Purified water 1.02 Ninocol 8010 0.51i' Fluidity Parafine 10. Or total 100. Or An ointment having the above formulation was prepared according to Example 1.
この軟膏は酪酸プロピオン酸ヒドロコルチゾンｉたは硫
ばゲンタマイシンの結晶もしくは析出物・が認められな
かった、
実施例３
フルオシノロンアセトニド ０．０２５ｆ硫酸ゲンタマ
イシン ０２２力価
プロピレングリコール ７． Ｏｒ
精製水 ３０２
ピロ亜硫酸ナトリウム ０．２２
二ノコ一ルＭＧＳ ５．０７
計 １００．Ｏｒ
実施例１に準じて上記配合の軟膏を調製した。No crystals or precipitates of hydrocortisone butyrate propionate or gentamicin sulfate were observed in this ointment. Example 3 Fluocinolone acetonide 0.025f Gentamicin sulfate 022 titer Propylene glycol Or Purified water 302 Sodium pyrosulfite 0.22 Ninokoil MGS 5.07 Total 100. Or An ointment having the above formulation was prepared according to Example 1.
この軟膏はフルオシノロンアセトニドまたは硫酸ゲンタ
マイシンの結晶もしくは析出物が認められなかった。No crystals or precipitates of fluocinolone acetonide or gentamicin sulfate were observed in this ointment.
実施例４ 酪酸ヒドロコルチゾン ０．２１ 硫酸ゲンタマイシン ０．１２力価 プロピレングリコール ５．０２ 精製水 １６ロ２ ピロ亜硫酸ナトリウム ０．０４ ｒ ＝ 、：７−ルＰＭＢ ３．Ｏｆ パラフィン ５．０２ 計 １００．Ｏｆ 実施例１に準じて上記配合の軟膏を調製した。Example 4 Hydrocortisone butyrate 0.21 Gentamicin sulfate 0.12 titer Propylene glycol 5.02 Purified water 16 ro 2 Sodium pyrosulfite 0.04 r =, :7-ru PMB 3. Of Paraffin 5.02 Total 100. Of An ointment having the above formulation was prepared according to Example 1.
この軟膏は硫酸ゲンタマイシンまたは酪酸プロピオンば
ヒドロコルチゾンの結晶もしくは析出物が認められなか
った。No crystals or precipitates of gentamicin sulfate or propion butyrate or hydrocortisone were observed in this ointment.
特許出願人 大正製薬株式会社 代理人 弁理士 北 川 富 造Patent applicant: Taisho Pharmaceutical Co., Ltd. Agent Patent Attorney Tomizo Kitagawa
Claims (1)
０〜１０．０重量部、界面活性剤を０１〜６．０′重量
部、高級パラフィン系炭化水素を９７〜７５重量部、ピ
ａ亜硫・酸ナトリウムを０．０２〜０．２重量部からな
る混合物を基剤とし、製品１２中に硫酸ゲンタマイシン
０２〜５ ｍｙ力価と副腎皮質ホルモン０．２〜５ ｍ
ｇを含有させることを特徴とする軟膏。(1) Alcohol and water in a ratio of 1:1 to 9°1
0 to 10.0 parts by weight, 01 to 6.0 parts by weight of surfactant, 97 to 75 parts by weight of higher paraffinic hydrocarbon, and 0.02 to 0.2 parts by weight of sodium pia sulfite. The product 12 is based on a mixture consisting of gentamicin sulfate 02-5 my titer and corticosteroid 0.2-5 m
An ointment characterized by containing g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59012696A JPS60156608A (en) | 1984-01-26 | 1984-01-26 | Ointment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59012696A JPS60156608A (en) | 1984-01-26 | 1984-01-26 | Ointment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60156608A true JPS60156608A (en) | 1985-08-16 |
| JPH0219090B2 JPH0219090B2 (en) | 1990-04-27 |
Family
ID=11812542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59012696A Granted JPS60156608A (en) | 1984-01-26 | 1984-01-26 | Ointment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60156608A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0217141A2 (en) * | 1985-09-28 | 1987-04-08 | Beiersdorf Aktiengesellschaft | W/O creams containing 17-propionate-21-acetate |
| EP0217146A2 (en) * | 1985-09-28 | 1987-04-08 | Beiersdorf Aktiengesellschaft | W/O creams containing hydrocortisone diesters |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0922261A (en) * | 1995-07-06 | 1997-01-21 | Shigeru Sugiura | Optical fiber display containing movable type solar battery built in |
-
1984
- 1984-01-26 JP JP59012696A patent/JPS60156608A/en active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0217141A2 (en) * | 1985-09-28 | 1987-04-08 | Beiersdorf Aktiengesellschaft | W/O creams containing 17-propionate-21-acetate |
| EP0217146A2 (en) * | 1985-09-28 | 1987-04-08 | Beiersdorf Aktiengesellschaft | W/O creams containing hydrocortisone diesters |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0219090B2 (en) | 1990-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1067409A (en) | Anti-inflammatory composition containing corticosteroids | |
| US3592930A (en) | Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle | |
| US5061700A (en) | Glyceryl acetate ointment vehicles | |
| US4017615A (en) | Propylene carbonate ointment vehicle | |
| US8828444B2 (en) | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel | |
| SI3146969T1 (en) | Ointment for the topical treatment of psoriasis | |
| IE850146L (en) | Topical drug release system | |
| CN101340916A (en) | Preparation for external use having improved temporal stability of steroid | |
| PL177592B1 (en) | Novel composition | |
| JPS5815909A (en) | Antimycotic agent for external use | |
| JPS62164623A (en) | Medicinal composition | |
| CA1182048A (en) | Topically administrable pharmaceutical compositions containing anti-inflammatory steroids | |
| PL202852B1 (en) | Nimesulide containing topical pharmaceutical compositions | |
| EP0473811B1 (en) | Ointment containing deprodone proprionate | |
| JP2006028123A (en) | Emulsion skin care preparation for external use | |
| GB2443162A (en) | Spray foaming dosage form comprising betamethasone valerate | |
| US3888995A (en) | Fatty alcohol-propylene glycol vehicle | |
| GB2239600A (en) | Ibuprofen triturates and topical compositions containing same | |
| JPS60156608A (en) | Ointment | |
| JPH0676327B2 (en) | Steroid ointment formulation | |
| JPH0676328B2 (en) | Steroid cream formulation | |
| US4794107A (en) | Ointment | |
| JP2016520656A (en) | Corticosteroid composition | |
| US6979454B1 (en) | Biologically active composition | |
| JPS5933211A (en) | Oleaginous ointment |